Valneva SEWBO:VLA +0.63%58 Market Cap is €420.1 Mil as of Jun. 30, 2026. GuruFocus rates WBO:VLA with a GF Score™ of 58/100 and a GF Value™ of €2.49 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,428 Biotechnology companies, Valneva SE ranks better than 70.52% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Valneva SE's share price for the quarter that ended in Mar. 2026 was €2.81. Valneva SE's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 173.8 Mil. Therefore, Valneva SE's market cap for the quarter that ended in Mar. 2026 was €488.2 Mil.
Valneva SE's quarterly market cap
declined
from Sep. 2025 (€842.5 Mil) to Dec. 2025 (€650.7 Mil) and
declined
from Dec. 2025 (€650.7 Mil) to Mar. 2026 (€488.2 Mil).
Valneva SE's annual market cap
declined
from Dec. 2023 (€660.6 Mil) to Dec. 2024 (€341.0 Mil) but then
increased
from Dec. 2024 (€341.0 Mil) to Dec. 2025 (€650.7 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Valneva SE's Enterprise Value for Today is €524.3 Mil.
Valneva SE (WBO:VLA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Valneva SE Market Cap Related Terms
Valneva SE Market Cap Historical Data
* Premium members only.
The historical data trend for Valneva SE's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:VLA vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Valneva SE's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valneva SE Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valneva SE's Market Cap distribution charts can be found below:
* The bar in red indicates where Valneva SE's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Valneva SE's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valneva SE (WBO:VLA) has a Market Cap of €420.1 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Valneva SE and its competitors. According to the industry distribution chart, Valneva SE ranks #421 out of 1428 companies in the Biotechnology industry, placing it in the top 29.5%.
Is Valneva SE's Market Cap too high?
Valneva SE's current Market Cap is €420.1 Mil. Based on the distribution chart, Valneva SE ranks #421 out of 1428 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Valneva SE has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #421 out of 1428 companies for Market Cap. This puts Valneva SE in the upper half of its industry. The industry median Market Cap is 119.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.44, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Valneva SE and its competitors. For the Biotechnology industry, the median Market Cap is 119.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valneva SE's current Market Cap is €420.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (WBO:VLA) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.49, compared to a current price of €2.24 — trading 9.9% below its estimated fair value. The current Market Cap is €420.1 Mil. Valneva SE's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Valneva SE (WBO:VLA), the current Market Cap is €420.1 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valneva SE (WBO:VLA) Overvalued in 2026?
Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued.
The current stock price of €2.24 is trading 9.9% below its estimated GF Value™ of €2.49.
GuruFocus considers Valneva SE to be Modestly Undervalued.
Key valuation signals for WBO:VLA:
Market Cap: €420.1 Mil
GF Value™: €2.49 vs. price of €2.24 (9.9% below fair value)
No single metric tells the full story. See the WBO:VLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
58GF Score
Get the complete analysis for WBO:VLA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:VLA has been successfully added to your 
